This AOP is licensed under the BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.

AOP: 4

Title

A descriptive phrase which references both the Molecular Initiating Event and Adverse Outcome.It should take the form “MIE leading to AO”. For example, “Aromatase inhibition leading to reproductive dysfunction” where Aromatase inhibition is the MIE and reproductive dysfunction the AO. In cases where the MIE is unknown or undefined, the earliest known KE in the chain (i.e., furthest upstream) should be used in lieu of the MIE and it should be made clear that the stated event is a KE and not the MIE.  More help

Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1

Short name
A name that succinctly summarises the information from the title. This name should not exceed 90 characters. More help
EcR agonism leading to mortality via suppression of Ftz-f1
The current version of the Developer's Handbook will be automatically populated into the Handbook Version field when a new AOP page is created.Authors have the option to switch to a newer (but not older) Handbook version any time thereafter. More help
Handbook Version v1.0

Graphical Representation

A graphical representation of the AOP.This graphic should list all KEs in sequence, including the MIE (if known) and AO, and the pair-wise relationships (links or KERs) between those KEs. More help
Click to download graphical representation template Explore AOP in a Third Party Tool

Authors

The names and affiliations of the individual(s)/organisation(s) that created/developed the AOP. More help

You Song and Knut Erik Tollefsen Norwegian Institute for Water Research (NIVA), Økernveien 94, N-0579 Oslo, Norway

Point of Contact

The user responsible for managing the AOP entry in the AOP-KB and controlling write access to the page by defining the contributors as described in the next section.   More help
Knut Erik Tollefsen   (email point of contact)

Contributors

Users with write access to the AOP page.  Entries in this field are controlled by the Point of Contact. More help
  • Knut Erik Tollefsen
  • You Song

Coaches

This field is used to identify coaches who supported the development of the AOP.Each coach selected must be a registered author. More help

OECD Information Table

Provides users with information concerning how actively the AOP page is being developed and whether it is part of the OECD Workplan and has been reviewed and/or endorsed. OECD Project: Assigned upon acceptance onto OECD workplan. This project ID is managed and updated (if needed) by the OECD. OECD Status: For AOPs included on the OECD workplan, ‘OECD status’ tracks the level of review/endorsement of the AOP . This designation is managed and updated by the OECD. Journal-format Article: The OECD is developing co-operation with Scientific Journals for the review and publication of AOPs, via the signature of a Memorandum of Understanding. When the scientific review of an AOP is conducted by these Journals, the journal review panel will review the content of the Wiki. In addition, the Journal may ask the AOP authors to develop a separate manuscript (i.e. Journal Format Article) using a format determined by the Journal for Journal publication. In that case, the journal review panel will be required to review both the Wiki content and the Journal Format Article. The Journal will publish the AOP reviewed through the Journal Format Article. OECD iLibrary published version: OECD iLibrary is the online library of the OECD. The version of the AOP that is published there has been endorsed by the OECD. The purpose of publication on iLibrary is to provide a stable version over time, i.e. the version which has been reviewed and revised based on the outcome of the review. AOPs are viewed as living documents and may continue to evolve on the AOP-Wiki after their OECD endorsement and publication.   More help
OECD Project # OECD Status Reviewer's Reports Journal-format Article OECD iLibrary Published Version
This AOP was last modified on October 02, 2025 04:18

Revision dates for related pages

Page Revision Date/Time
Increase, Ecdysone receptor hyperactivation September 29, 2025 04:47
Decrease, Circulating ecdysis triggering hormone May 24, 2018 16:34
Increase, Nuclear receptor E75b gene expression May 24, 2018 16:32
Decrease, Fushi tarazu factor-1 gene expression September 26, 2025 04:58
Decrease, Circulating crustacean cardioactive peptide May 24, 2018 16:37
Decrease, Ecdysis motor program activity September 29, 2025 04:18
Decrease, Abdominal muscle contraction May 24, 2018 16:41
Increase, Incomplete ecdysis May 24, 2018 16:41
Increase, Mortality October 26, 2020 05:18
Increase, EcR hyperactivation leads to Increase, E75b expression February 09, 2017 03:33
Increase, E75b expression leads to Decrease, Ftz-f1 expression February 09, 2017 03:33
Decrease, Ftz-f1 expression leads to Decrease, Circulating ETH February 09, 2017 03:34
Decrease, Circulating ETH leads to Decrease, Circulating CCAP February 09, 2017 03:34
Decrease, Circulating CCAP leads to Decrease, Ecdysis motor program activity February 09, 2017 03:35
Decrease, Ecdysis motor program activity leads to Decrease, Abdominal muscle contraction September 29, 2025 04:17
Decrease, Abdominal muscle contraction leads to Increase, Incomplete ecdysis December 03, 2016 16:38
Increase, Incomplete ecdysis leads to Increase, Mortality December 03, 2016 16:38
Tebufenozide February 09, 2017 03:06
20-hydroxyecdysone February 09, 2017 03:06
Ponasterone A February 09, 2017 03:06
Methoxyfenozide February 09, 2017 03:42
Halofenozide February 06, 2017 12:28
Chromafenozide February 09, 2017 03:41
Cyasterone February 09, 2017 03:42
Makisterone A February 09, 2017 03:43
Inokosterone February 09, 2017 03:43
Ecdysone February 09, 2017 03:43
RH-5849 February 09, 2017 03:43

Abstract

A concise and informative summation of the AOP under development that can stand-alone from the AOP page. The aim is to capture the highlights of the AOP and its potential scientific and regulatory relevance. More help

This Adverse Outcome Pathway (AOP) describes how hyperactivation of the ecdysone receptor (EcR) in arthropods can lead to lethal molting disruption and mortality. Binding of natural ligands (ecdysteroids) to EcR is critical for regulating molting and metamorphosis in insects and crustaceans. However, inappropriate or prolonged activation of EcR by exogenous chemicals disrupts the tightly regulated temporal gene expression cascade required for successful ecdysis. Key events (KEs) include altered expression of early transcription factors (E75B, Ftz-f1), reduction of circulating neuropeptides (CCAP, ETH), impaired motor program activity, and suppression of abdominal muscle contraction, ultimately resulting in incomplete ecdysis and death. This AOP provides mechanistic understanding relevant for environmental chemical safety assessment, particularly regarding pesticides and other compounds targeting insect endocrine systems.

AOP Development Strategy

Context

Used to provide background information for AOP reviewers and users that is considered helpful in understanding the biology underlying the AOP and the motivation for its development.The background should NOT provide an overview of the AOP, its KEs or KERs, which are captured in more detail below. More help

The development of this AOP is motivated by regulatory needs to understand and predict the impacts of insect growth regulators and other endocrine-active chemicals that target EcR. Such compounds are widely used in pest control but pose risks to non-target arthropods, including pollinators and aquatic invertebrates. The AOP formalizes knowledge of conserved molting endocrine pathways to support hazard identification and potential regulatory screening frameworks.

Strategy

Provides a description of the approaches to the identification, screening and quality assessment of the data relevant to identification of the key events and key event relationships included in the AOP or AOP network.This information is important as a basis to support the objective/envisaged application of the AOP by the regulatory community and to facilitate the reuse of its components.  Suggested content includes a rationale for and description of the scope and focus of the data search and identification strategy/ies including the nature of preliminary scoping and/or expert input, the overall literature screening strategy and more focused literature surveys to identify additional information (including e.g., key search terms, databases and time period searched, any tools used). More help

The AOP was developed based on structured literature reviews and expert knowledge. Key sources included primary research on EcR signaling, molting neuropeptides (ETH, CCAP), transcriptional cascades in Drosophila melanogaster and other model insects, as well as crustacean endocrinology. Literature searches were conducted in PubMed, Web of Science, and Scopus using terms such as ecdysone receptor agonists, ecdysis motor program, insect molting disruption, 20-hydroxyecdysone, and ecdysteroid signaling. Priority was given to studies demonstrating experimental perturbation of EcR or downstream KEs and their effects on molting success and survival. Reviews and AOP frameworks (e.g., OECD guidance) were used to ensure structured evaluation and alignment with regulatory relevance.

Summary of the AOP

This section is for information that describes the overall AOP.The information described in section 1 is entered on the upper portion of an AOP page within the AOP-Wiki. This is where some background information may be provided, the structure of the AOP is described, and the KEs and KERs are listed. More help

Events:

Molecular Initiating Events (MIE)
An MIE is a specialised KE that represents the beginning (point of interaction between a prototypical stressor and the biological system) of an AOP. More help
Key Events (KE)
A measurable event within a specific biological level of organisation. More help
Adverse Outcomes (AO)
An AO is a specialized KE that represents the end (an adverse outcome of regulatory significance) of an AOP. More help
Type Event ID Title Short name
MIE 103 Increase, Ecdysone receptor hyperactivation Increase, EcR hyperactivation
KE 1264 Increase, Nuclear receptor E75b gene expression Increase, E75b expression
KE 1265 Decrease, Fushi tarazu factor-1 gene expression Decrease, Ftz-f1 expression
KE 988 Decrease, Circulating ecdysis triggering hormone Decrease, Circulating ETH
KE 1266 Decrease, Circulating crustacean cardioactive peptide Decrease, Circulating CCAP
KE 1267 Decrease, Ecdysis motor program activity Decrease, Ecdysis motor program activity
KE 993 Decrease, Abdominal muscle contraction Decrease, Abdominal muscle contraction
AO 990 Increase, Incomplete ecdysis Increase, Incomplete ecdysis
AO 350 Increase, Mortality Increase, Mortality

Relationships Between Two Key Events (Including MIEs and AOs)

This table summarizes all of the KERs of the AOP and is populated in the AOP-Wiki as KERs are added to the AOP.Each table entry acts as a link to the individual KER description page. More help

Network View

This network graphic is automatically generated based on the information provided in the MIE(s), KEs, AO(s), KERs and Weight of Evidence (WoE) summary tables. The width of the edges representing the KERs is determined by its WoE confidence level, with thicker lines representing higher degrees of confidence. This network view also shows which KEs are shared with other AOPs. More help

Prototypical Stressors

A structured data field that can be used to identify one or more “prototypical” stressors that act through this AOP. Prototypical stressors are stressors for which responses at multiple key events have been well documented. More help

Life Stage Applicability

The life stage for which the AOP is known to be applicable. More help
Life stage Evidence
Juvenile High
Adult High

Taxonomic Applicability

Latin or common names of a species or broader taxonomic grouping (e.g., class, order, family) can be selected.In many cases, individual species identified in these structured fields will be those for which the strongest evidence used in constructing the AOP was available. More help
Term Scientific Term Evidence Link
insects insects High NCBI
crustaceans Daphnia magna Moderate NCBI
Arthropoda Arthropoda High NCBI

Sex Applicability

The sex for which the AOP is known to be applicable. More help
Sex Evidence
Unspecific Moderate

Overall Assessment of the AOP

Addressess the relevant biological domain of applicability (i.e., in terms of taxa, sex, life stage, etc.) and Weight of Evidence (WoE) for the overall AOP as a basis to consider appropriate regulatory application (e.g., priority setting, testing strategies or risk assessment). More help

The overall weight of evidence supporting this AOP is strong, with high biological plausibility and multiple lines of empirical support linking EcR hyperactivation to lethal molting disruption. The key endocrine and neuropeptide signaling pathways involved are highly conserved across arthropods, increasing confidence in broad taxonomic applicability, particularly to insects and crustaceans undergoing ecdysis. Essentiality of key events is well demonstrated through genetic and pharmacological manipulations, and direct causal linkages between upstream molecular initiating events and downstream organism-level outcomes are supported by both in vitro and in vivo studies. While quantitative understanding remains incomplete, especially regarding cross-species dose-response relationships, the evidence base is sufficient to support application in chemical screening, prioritization, and risk assessment. The AOP is considered reliable for use in evaluating the hazards of EcR agonists and related endocrine-active chemicals, with clear regulatory relevance to the assessment of insect growth regulators and protection of non-target arthropods.

Domain of Applicability

Addressess the relevant biological domain(s) of applicability in terms of sex, life-stage, taxa, and other aspects of biological context. More help
  • Taxa: Arthropods, primarily insects (Diptera, Lepidoptera, Coleoptera) and crustaceans.

  • Life stage: Juvenile and larval stages undergoing molting.

  • Sex: Both sexes are equally affected, as molting regulation is not sex-specific.

  • Other considerations: The pathway is most relevant in holometabolous insects but is applicable across arthropods where molting is controlled by EcR signaling.

Essentiality of the Key Events

The essentiality of KEs can only be assessed relative to the impact of manipulation of a given KE (e.g., experimentally blocking or exacerbating the event) on the downstream sequence of KEs defined for the AOP. Consequently, evidence supporting essentiality is assembled on the AOP page, rather than on the independent KE pages that are meant to stand-alone as modular units without reference to other KEs in the sequence. The nature of experimental evidence that is relevant to assessing essentiality relates to the impact on downstream KEs and the AO if upstream KEs are prevented or modified. This includes: Direct evidence: directly measured experimental support that blocking or preventing a KE prevents or impacts downstream KEs in the pathway in the expected fashion. Indirect evidence: evidence that modulation or attenuation in the magnitude of impact on a specific KE (increased effect or decreased effect) is associated with corresponding changes (increases or decreases) in the magnitude or frequency of one or more downstream KEs. More help
  • EcR hyperactivation (MIE): Genetic or pharmacological overactivation prevents correct timing of molting cascades, leading to lethality.

  • E75B and Ftz-f1 expression changes: Knockout or overexpression experiments demonstrate disruption of subsequent endocrine signals and molting success.

  • Circulating ETH/CCAP: Blocking or reducing peptide release suppresses ecdysis behavior. Rescue experiments with exogenous peptides restore motor program activity.

  • Motor program activity and abdominal contractions: Neurophysiological studies show that impaired muscle activity directly prevents exuviation.

  • Incomplete ecdysis: Universally essential for linking endocrine dysfunction to mortality.

Overall, essentiality of KEs is supported by direct experimental evidence in multiple model arthropods.

Evidence Assessment

Addressess the biological plausibility, empirical support, and quantitative understanding from each KER in an AOP. More help

KER 103 → 1264 (EcR hyperactivation → Increased E75B expression)

  • Biological plausibility: Strong. E75B is a primary-response gene in the ecdysone signaling cascade. Overactivation of EcR drives prolonged or elevated expression of E75B.

  • Empirical support: Multiple in vitro and in vivo studies (e.g., Drosophila, lepidopterans) show dose-dependent induction of E75B following EcR agonist exposure.

  • Uncertainties: Quantitative thresholds vary across taxa.

KER 103 → 1265 (EcR hyperactivation → Decreased Ftz-f1 expression)

  • Biological plausibility: Strong. Ftz-f1 is normally induced after a decline in ecdysone signaling, serving as a competence factor for subsequent developmental transitions. Sustained EcR activity suppresses Ftz-f1 expression.

  • Empirical support: Genetic experiments in Drosophila demonstrate that EcR hyperactivation prevents Ftz-f1 induction, leading to molting defects.

  • Uncertainties: The precise timing of downregulation differs between insect species.

KER 1265 → 998 (Decreased Ftz-f1 expression → Decreased circulating ETH)

  • Biological plausibility: Moderate to strong. ETH release from Inka cells requires proper transcriptional programming, in which Ftz-f1 plays a permissive role.

  • Empirical support: ETH levels are reduced in Ftz-f1 mutant or RNAi knockdown insects, with corresponding ecdysis failure.

  • Uncertainties: Direct mechanistic links in crustaceans are less studied.

KER 1264 → 1266 (Increased E75B expression → Decreased circulating CCAP)

  • Biological plausibility: Moderate. E75B dysregulation affects downstream neural peptide release patterns, including crustacean cardioactive peptide (CCAP).

  • Empirical support: Studies in Manduca sexta and Drosophila show disrupted CCAP neuron activation in response to EcR agonists.

  • Uncertainties: Empirical dose-response data linking E75B overexpression directly to CCAP suppression are limited.

KER 1266 → 1267 (Decreased circulating CCAP → Decreased ecdysis motor program activity)

  • Biological plausibility: Strong. CCAP is required to initiate and maintain the motor patterns driving ecdysis behavior.

  • Empirical support: Ablation or silencing of CCAP neurons abolishes normal ecdysis behavior in insects. Exogenous CCAP restores motor program activity in some experimental systems.

  • Uncertainties: Quantitative thresholds for peptide levels triggering full motor program are not well established.

KER 998 → 993 (Decreased circulating ETH → Decreased abdominal muscle contraction)

  • Biological plausibility: Strong. ETH directly triggers ecdysis motor output by activating central nervous system circuits.

  • Empirical support: ETH knockout or peptide inhibition prevents abdominal contractions in Drosophila larvae. ETH injection can rescue the phenotype.

  • Uncertainties: Effects may be stage-dependent.

KER 1267 → 990 (Decreased ecdysis motor program activity → Incomplete ecdysis)

  • Biological plausibility: Strong. Motor program activity is essential for successful shedding of the old cuticle.

  • Empirical support: Neurophysiological and behavioral studies show that impaired motor activity directly correlates with failed or incomplete ecdysis.

  • Uncertainties: Variation in motor outputs among species may influence severity.

KER 993 → 990 (Decreased abdominal muscle contraction → Incomplete ecdysis)

  • Biological plausibility: Strong. Abdominal contractions generate the mechanical force required for cuticle shedding.

  • Empirical support: Pharmacological or genetic inhibition of abdominal muscle contraction prevents complete ecdysis in Drosophila and other insects.

  • Uncertainties: Contribution of other body muscles (e.g., thoracic) not fully quantified.

KER 990 → 350 (Incomplete ecdysis → Increased mortality)

  • Biological plausibility: Strong. Inability to shed the old cuticle is incompatible with survival.

  • Empirical support: High mortality rates are consistently observed in laboratory and field studies where molting is disrupted by EcR agonists or neuropeptide blockers.

  • Uncertainties: Mortality timing (immediate vs delayed) may vary with species and stage.

Known Modulating Factors

Modulating factors (MFs) may alter the shape of the response-response function that describes the quantitative relationship between two KES, thus having an impact on the progression of the pathway or the severity of the AO.The evidence supporting the influence of various modulating factors is assembled within the individual KERs. More help
  • Temperature: Affects hormone turnover and molting periodicity.

  • Nutritional status: Influences steroid hormone synthesis and peptide release.

  • Species-specific sensitivity: Different insects and crustaceans vary in susceptibility to EcR agonists.

  • Developmental stage: Early versus late larval stages may have differing vulnerability.

Modulating Factor (MF) Influence or Outcome KER(s) involved
     

Quantitative Understanding

Optional field to provide quantitative weight of evidence descriptors.  More help

Quantitative relationships between EcR activation and downstream transcriptional responses are partially characterized, especially in Drosophila. Dose-response data for diacylhydrazine insecticides provide empirical linkage between exposure and incomplete ecdysis. However, quantitative models are still limited and largely taxon-specific.

Considerations for Potential Applications of the AOP (optional)

Addressess potential applications of an AOP to support regulatory decision-making.This may include, for example, possible utility for test guideline development or refinement, development of integrated testing and assessment approaches, development of (Q)SARs / or chemical profilers to facilitate the grouping of chemicals for subsequent read-across, screening level hazard assessments or even risk assessment. More help

This AOP has clear utility for both scientific and regulatory applications related to the environmental assessment of endocrine-active substances targeting arthropod molting. Because EcR is the primary molecular target of many insect growth regulators (IGRs), this pathway provides a mechanistic framework for interpreting how chemical binding at the receptor level translates to population-level adverse outcomes such as mortality.

From a regulatory perspective, the AOP can inform the development and refinement of OECD test guidelines addressing arthropod development and molting. It can also support the design of integrated approaches to testing and assessment (IATA), in which data from in vitro receptor-binding assays, transcriptomic biomarkers (e.g., E75B, Ftz-f1), and neuropeptide measurements can be combined with higher-tier organismal studies to streamline hazard characterization. Furthermore, the pathway may facilitate the identification of molecular biomarkers that can be incorporated into early screening assays, reducing reliance on animal-intensive in vivo tests.

The AOP is also relevant for chemical grouping and read-across approaches, particularly for compounds within the diacylhydrazine class and other EcR agonists. Structure–activity relationship ((Q)SAR) models or chemical profilers trained on these endpoints could help predict EcR activity and prioritize substances for further testing.

For ecological risk assessment, this AOP highlights the potential for population-level impacts on non-target arthropods, including beneficial insects (e.g., pollinators) and aquatic crustaceans. Given the essential role of molting for growth and reproduction, disruptions captured in this pathway provide a mechanistic basis to link molecular initiating events to ecologically relevant endpoints.

Overall, this AOP offers opportunities to improve chemical safety decision-making by providing a structured framework to integrate mechanistic data into regulatory contexts, enabling screening, prioritization, and risk assessment of chemicals that act through EcR hyperactivation.

References

List of the literature that was cited for this AOP. More help

Song, Y.; Villeneuve, D. L.; Toyota, K.; Iguchi, T.; Tollefsen, K. E., 2017. Ecdysone receptor agonism leading to lethal molting disruption in arthropods: review and adverse outcome pathway development. Environ Sci Technol, 51, (8), 4142-4157.

Song, Y., Evenseth, L.M., Iguchi, T., Tollefsen, K.E., 2017. Release of chitobiase as an indicator of potential molting disruption in juvenile Daphnia magna exposed to the ecdysone receptor agonist 20-hydroxyecdysone. J Toxicol Environ Health A, 1-9

Fay, K. A., Villeneuve, D. L., LaLone, C. A., Song, Y., Tollefsen, K. E. and Ankley, G. T., 2017. Practical approaches to adverse outcome pathway (AOP) development and weight of evidence evaluation as illustrated by ecotoxicological case studies. Environ. Toxicol. Chem. 36(6):1429-1449.

Miyakawa, H., Sato, T., Song, Y., Tollefsen, K.E., Iguchi, T., 2017. Ecdysteroid and juvenile hormone biosynthesis, receptors and their signaling in the freshwater microcrustacean Daphnia. J Steroid Biochem Mol Biol. pii: S0960-0760(17), 30370-30379.